Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

2.550 -0.280 (-9.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 358,889
Open 2.730
Bid (Size) 2.540 (40)
Ask (Size) 2.550 (17)
Prev. Close 2.830
Today's Range 2.540 - 2.810
52wk Range 2.670 - 10.13
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025. 
Via Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-47.3%
-47.3%
1 Month
-21.3%
-21.3%
3 Month
-47.3%
-47.3%
6 Month
-34.1%
-34.1%
1 Year
-71.9%
-71.9%

More News

Read More
These stocks are moving in today's pre-market session
Via Chartmill
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
Via Benzinga
Expert Ratings For Fulcrum Therapeutics
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Earnings Preview: Fulcrum Therapeutics
Via Benzinga
Fulcrum Therapeutics's Earnings Outlook
Via Benzinga
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Fulcrum Therapeutics to Participate in Upcoming December Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
Via Talk Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
The current price of Fulcrum Therapeutics, Inc. - Common Stock is 2.550
When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 04/03/25 04:00 PM ET
What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 157.49M
How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
Fulcrum Therapeutics, Inc. - Common Stock has 157M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.